William Hampton Bradley

William Hampton Bradley

Auto-generated profile, based on publicly available information

William Hampton Bradley

Medical College of Wisconsin, Milwaukee, WI

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
PDPaul DiSilvestro
Paul DiSilvestro
SBSusana Banerjee
Susana Banerjee
NCNicoletta Colombo
Nicoletta Colombo
GSGiovanni Scambia
Giovanni Scambia
BKByoung-Gie Kim
Byoung-Gie Kim
OIon behalf of the SOLO1 Investigators
on behalf of the SOLO1 Investigators
PURPOSE: In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986 ), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 (BRCA) mutation. We report overall survival (OS) after a 7-year follow-up, a clinically relevant time point and the longest follow-up for any poly(ADP-ribose) polymerase inhibitor in the first-line setting. METHODS: This double-blind phase III trial randomly assigned patients with newly diagnosed advanced ovarian cancer and a BRCA mutation in clinical response to platinum-based chemotherapy to maintenance olaparib (n = 260) or placebo (n = 131) for up to 2 years. A prespecified descriptive analysis of OS, a secondary end point, was conducted after a 7-year follow-up. RESULTS: The median duration of treatment was 24.6 months with olaparib and 13.9 months with placebo, and the median follow-up was 88.9 and 87.4 months, respectively. The hazard ratio for OS was 0.55 (95% CI, 0.40 to 0.76; P = .0004 [ P < .0001 required to declare statistical significance]). At 7 years, 67.0% of olaparib patients versus 46.5% of placebo patients were alive, and 45.3% versus 20.6%, respectively, were alive and had not received a first subsequent treatment (Kaplan-Meier estimates). The incidence of myelodysplastic syndrome and acute myeloid leukemia remained low, and new primary malignancies remained balanced between treatment groups. CONCLUSION: Results indicate a clinically meaningful, albeit not statistically significant according to prespecified criteria, improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation and support the use of maintenance olaparib to achieve long-term remission in this setting; the potential for cure may also be enhanced. No new safety signals were observed during long-term follow-up.

1 January 2023 in JCO Clinical Cancer Informatics
Verified
Journal Article
Open access
XYXiang Yin
Xiang Yin
RDRuthanna Davi
Ruthanna Davi
ELElizabeth B. Lamont
Elizabeth B. Lamont
PTPremal H. Thaker
Premal H. Thaker
WBWilliam H. Bradley
William H. Bradley
NBNicholas Borys
Nicholas Borys
PURPOSE: To inform continued development of the novel immune agent GEN-1, we compared ovarian cancer patients' end points from a neoadjuvant single-arm phase IB study with those of similar historic clinical trial (HCT) patients who received standard neoadjuvant chemotherapy. METHODS: Applying OVATION-1 trial (ClinicalTrials.gov identifier: NCT02480374 ) inclusion and exclusion criteria to Medidata HCT data, we identified historical trial patients for comparison. Integrating patient-level Medidata historic trial data (N = 41) from distinct neoadjuvant ovarian phase I-III trials with patient-level OVATION-1 data (N = 18), we selected Medidata patients with similar baseline characteristics as OVATION-1 patients using propensity score methods to create an external control arm (ECA). RESULTS: Fifteen OVATION-1 patients (15 of 18, 83%) were matched to 15 (37%, 15 of 41) Medidata historical trial control patients. Matching attenuated preexisting differences in attributes between the groups. The median progression-free survival time was not reached by the OVATION-1 group and was 15.8 months (interquartile range, 11.40 months to nonestimable) for the ECA. The hazard of progression was 0.53 (95% CI, 0.16 to 1.73), favoring GEN-1 patients. Compared with ECA patients, OVATION-1 patients had more nausea, fatigue, chills, and infusion-related reactions. CONCLUSION: Comparing results of a single-arm early-phase trial to those of a rigorously matched HCT ECA yielded insights regarding comparative efficacy prior to a randomized controlled trial. The effect size estimate itself informed both the decision to continue development and the randomized phase II trial (ClinicalTrials.gov identifier: NCT03393884 ) sample size. The work illustrates the potential of HCT data to inform drug development.

30 June 2023 in Brachytherapy
Verified
Journal Article
Closed access
LMLindsey A. McAlarnen
Lindsey A. McAlarnen
CSChristina Small
Christina Small
LTLauren Tostrud
Lauren Tostrud
APAmy Y. Pan
Amy Y. Pan
BEBeth Erickson
Beth Erickson
WBWilliam H. Bradley
William H. Bradley

31 March 2023
Verified
Other
Open access
AGANJALI GEETHADEVI
ANJALI GEETHADEVI
ANAjay Nair
Ajay Nair
Deepak ParasharDeepak Parashar
Deepak Parashar
Zhiqiang KuZhiqiang Ku
Zhiqiang Ku
WXWei Xiong
Wei Xiong
PCPradeep Chaluvally-Raghavan
Pradeep Chaluvally-Raghavan
Although patients with advanced ovarian cancer may respond initially to treatment, disease relapse is common, and nearly 50% of patients do not survive beyond five years, indicating an urgent need for improved therapies. To identify new therapeutic targets, we performed single-cell and nuclear RNA-seq data set analyses on 17 human ovarian cancer specimens, revealing the oncostatin M receptor (OSMR) as highly expressed in ovarian cancer cells. Conversely, oncostatin M (OSM), the ligand of OSMR, was highly expressed by tumor-associated macrophages and promoted proliferation and metastasis in cancer cells. Ovarian cancer cell lines and additional patient samples also exhibited elevated levels of OSMR when compared with other cell types in the tumor microenvironment or to normal ovarian tissue samples. OSMR was found to be important for ovarian cancer cell proliferation and migration. Binding of OSM to OSMR caused OSMR–IL6ST dimerization, which is required to produce oncogenic signaling cues for prolonged STAT3 activation. Human monoclonal antibody clones B14 and B21 directed to the extracellular domain of OSMR abrogated OSM-induced OSMR–IL6ST heterodimerization, promoted the internalization and degradation of OSMR, and effectively blocked OSMR-mediated signaling in vitro. Importantly, these antibody clones inhibited the growth of ovarian cancer cells in vitro and in vivo by suppressing oncogenic signaling through OSMR and STAT3 activation. Collectively, this study provides a proof of principle that anti-OSMR antibody can mediate disruption of OSM-induced OSMR–IL6ST dimerization and oncogenic signaling, thus documenting the preclinical therapeutic efficacy of human OSMR antagonist antibodies for immunotherapy in ovarian cancer.Significance:This study uncovers a role for OSMR in promoting ovarian cancer cell proliferation and metastasis by activating STAT3 signaling and demonstrates the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PTPremal H. Thaker
Premal H. Thaker
CICharles Leath III
Charles Leath III
WBWilliam Hampton Bradley
William Hampton Bradley
KMKathleen N. Moore
Kathleen N. Moore
NBNicholas Borys
Nicholas Borys
RARonald Alvarez
Ronald Alvarez
TPS5605 Background: This phase 1 study (NCT02480374) evaluates the use of weekly intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in combination with dose-dense weekly taxane and carboplatinum (T/C) every three weeks in newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal (EOC) cancer patients undergoing neoadjuvant therapy (NAC). Previous phase I study in platinum-sensitive EOC patients (n = 13) with escalating GEN-1 doses to 24 mg/m2 in combination T/C had an anti-tumor response of 17% complete response, 33% partial response and 42% stable disease (Anwer K. Gynecol Oncol. 2013 Oct;131(1):169-73). The primary objective of this study is to evaluate the tolerability and safety of GEN-1 with NAC in order to proceed with a phase 2 study. Secondary objectives are progression-free survival, pathological complete response, and response by CA-125. Translational research objectives include measuring levels of IL-12, IFN-γ, TNF-α, IL-10, TGF-β, and VEGF, determining the density of a wide range of immune activating and immune suppressing cells, and a comprehensive mRNA transcript panel for gene expression profile in the peritoneal cavity. Methods: Patient eligibility criteria: Females age > 18 years with newly diagnosed epithelial EOC not amenable to primary cytoreduction. Patients must not be on chronic steroids and have adequate renal, bone marrow, hepatic and neurologic functions. This protocol is a standard 3+3 design with a planned sample size up to 30 patients. Patients will receive GEN-1 at escalating dose levels from 36 mg/m2, 47 mg/m2, 61 mg/m2, 79 mg/m2, to 103 mg/m2 weekly for 8 treatments with concurrent T/C. After interval debulking patients do not receive further GEN-1 but continue on T/C. Patients are assessed for dose limiting toxicities and have tumor samples at time of diagnostic laparoscopy and interval debulking. After completion of therapy, patients are followed for every 3 months 2 years. As of January 31, 2016, 2 patients have completed dose level 1 and study enrollment continues. Clinical trial information: NCT02480374.

14 October 2026 in Molecular Therapy Oncology
Verified
Journal Article
Open access
MPMeenakshi Pradeep
Meenakshi Pradeep
IKIshaque Pulikkal Kadamberi
Ishaque Pulikkal Kadamberi
JGJasmine George
Jasmine George
YGYueying Gao
Yueying Gao
CDCamilla Dagum
Camilla Dagum
AOAkinyemi I. Ojesina
Akinyemi I. Ojesina